Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b

2022107 citationsletterhybrid Open Access

Authors

Jean-Jacques Kiladjian · Inserm

Christoph Klade · AOP Orphan (Austria)

Pencho Georgiev · Medical University Plovdiv

Dorota Krochmalczyk · Krakow Cardiovascular Research Institute

Liana Gercheva · University Hospital St. Marina

Miklós Egyed · Somogy Megyei Kaposi Mór Oktató Kórház

Petr Ďulíček ·

Abstract

Interferon alfa not only restores normal blood cell counts in patients with polycythemia vera (PV) but can diminish the mutant JAK2V617F allele burden After discontinuing long-term interferon therapy, hematologic responses may persist Allele burden declines gradually during interferon treatment

Topics & Keywords

Myeloproliferative Neoplasms: Diagnosis and Treatment Eosinophilic Disorders and Syndromes Cytokine Signaling Pathways and Interactions

UN Sustainable Development Goals

Zero hunger

Publication Details

Published in: Leukemia

Volume 36, Issue 5, pp. 1408-1411

DOI: 10.1038/s41375-022-01528-x

Field-Weighted Citation Impact: 15.76